APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody VEGF Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Monoclonal Antibody VEGF Inhibitors Market Outlook and Growth Opportunities 2026

27 December 2025191 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody VEGF Inhibitors Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody VEGF Inhibitors Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody VEGF Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody VEGF Inhibitors Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody VEGF Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody VEGF Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Monoclonal Antibody VEGF Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibody VEGF Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibody VEGF Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Monoclonal Antibody VEGF Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Monoclonal Antibody VEGF Inhibitors market include Amgen, Amneal Pharmaceuticals,, Celltrion Healthcare, Coherus BioSciences, Eli Lilly, Novartis, Pfizer, Roche and Boan Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Monoclonal Antibody VEGF Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monoclonal Antibody VEGF Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monoclonal Antibody VEGF Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Monoclonal Antibody VEGF Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Monoclonal Antibody VEGF Inhibitors Segment by Company

Amgen

Amneal Pharmaceuticals,

Celltrion Healthcare

Coherus BioSciences

Eli Lilly

Novartis

Pfizer

Roche

Boan Biotech

Jiangsu Hengrui Pharmaceuticals

Qilu Pharma

SinoCellTech

Innovent

Chia Tai Tianqing

Monoclonal Antibody VEGF Inhibitors Segment by Type

Bevacizumab

Brolucizumab

Faricimab

Ramucirumab

Ranibizumab

Other

Monoclonal Antibody VEGF Inhibitors Segment by Application

Degenerative Eye Diseases

Cancer

Other

Monoclonal Antibody VEGF Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Monoclonal Antibody VEGF Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Monoclonal Antibody VEGF Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Monoclonal Antibody VEGF Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Monoclonal Antibody VEGF Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody VEGF Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody VEGF Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody VEGF Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Monoclonal Antibody VEGF Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Monoclonal Antibody VEGF Inhibitors industry.

Chapter 3: Detailed analysis of Monoclonal Antibody VEGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Monoclonal Antibody VEGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Monoclonal Antibody VEGF Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Monoclonal Antibody VEGF Inhibitors Industry Trends Table 2. Monoclonal Antibody VEGF Inhibitors Industry Drivers Table 3. Monoclonal Antibody VEGF Inhibitors Industry Opportunities and Challenges Table 4. Monoclonal Antibody VEGF Inhibitors Industry Restraints Table 5. Global Monoclonal Antibody VEGF Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Monoclonal Antibody VEGF Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Monoclonal Antibody VEGF Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Monoclonal Antibody VEGF Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Monoclonal Antibody VEGF Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Monoclonal Antibody VEGF Inhibitors Company, Product Type & Application Table 13. Global Monoclonal Antibody VEGF Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Monoclonal Antibody VEGF Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Bevacizumab Table 18. Significant Companies of Brolucizumab Table 19. Significant Companies of Faricimab Table 20. Significant Companies of Ramucirumab Table 21. Significant Companies of Ranibizumab Table 22. Significant Companies of Other Table 23. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Type (2021-2026) Table 27. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Type (2027-2032) Table 28. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type (2021-2026) Table 32. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Degenerative Eye Diseases Table 34. Significant Companies of Cancer Table 35. Significant Companies of Other Table 36. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Application (2021-2026) Table 40. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Application (2027-2032) Table 41. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application (2021-2026) Table 45. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application (2027-2032) Table 46. Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2021-2026) & (K Units) Table 48. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2021-2026) Table 49. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2027-2032) & (K Units) Table 50. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2027-2032) Table 51. Global Monoclonal Antibody VEGF Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Region (2021-2026) Table 54. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Region (2027-2032) Table 56. Global Monoclonal Antibody VEGF Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Monoclonal Antibody VEGF Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Monoclonal Antibody VEGF Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 61. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2026) Table 62. Global Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 63. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2027-2032) Table 64. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Monoclonal Antibody VEGF Inhibitors Sales Value Market Share by Country (2021-2026) Table 66. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Monoclonal Antibody VEGF Inhibitors Sales Value Market Share by Country (2027-2032) Table 68. Amgen Company Information Table 69. Amgen Business Overview Table 70. Amgen Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Amgen Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 72. Amgen Recent Development Table 73. Amneal Pharmaceuticals, Company Information Table 74. Amneal Pharmaceuticals, Business Overview Table 75. Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 77. Amneal Pharmaceuticals, Recent Development Table 78. Celltrion Healthcare Company Information Table 79. Celltrion Healthcare Business Overview Table 80. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 82. Celltrion Healthcare Recent Development Table 83. Coherus BioSciences Company Information Table 84. Coherus BioSciences Business Overview Table 85. Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 87. Coherus BioSciences Recent Development Table 88. Eli Lilly Company Information Table 89. Eli Lilly Business Overview Table 90. Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Eli Lilly Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 92. Eli Lilly Recent Development Table 93. Novartis Company Information Table 94. Novartis Business Overview Table 95. Novartis Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Novartis Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 97. Novartis Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 102. Pfizer Recent Development Table 103. Roche Company Information Table 104. Roche Business Overview Table 105. Roche Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Roche Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 107. Roche Recent Development Table 108. Boan Biotech Company Information Table 109. Boan Biotech Business Overview Table 110. Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Boan Biotech Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 112. Boan Biotech Recent Development Table 113. Jiangsu Hengrui Pharmaceuticals Company Information Table 114. Jiangsu Hengrui Pharmaceuticals Business Overview Table 115. Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 117. Jiangsu Hengrui Pharmaceuticals Recent Development Table 118. Qilu Pharma Company Information Table 119. Qilu Pharma Business Overview Table 120. Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 122. Qilu Pharma Recent Development Table 123. SinoCellTech Company Information Table 124. SinoCellTech Business Overview Table 125. SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. SinoCellTech Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 127. SinoCellTech Recent Development Table 128. Innovent Company Information Table 129. Innovent Business Overview Table 130. Innovent Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Innovent Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 132. Innovent Recent Development Table 133. Chia Tai Tianqing Company Information Table 134. Chia Tai Tianqing Business Overview Table 135. Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product Portfolio Table 137. Chia Tai Tianqing Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Monoclonal Antibody VEGF Inhibitors Distributors List Table 141. Monoclonal Antibody VEGF Inhibitors Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Monoclonal Antibody VEGF Inhibitors Product Image Figure 2. Global Monoclonal Antibody VEGF Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Monoclonal Antibody VEGF Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Monoclonal Antibody VEGF Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Monoclonal Antibody VEGF Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Bevacizumab Image Figure 10. Brolucizumab Image Figure 11. Faricimab Image Figure 12. Ramucirumab Image Figure 13. Ranibizumab Image Figure 14. Other Image Figure 15. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Type (2021-2032) Figure 18. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type (2021-2032) Figure 21. Degenerative Eye Diseases Image Figure 22. Cancer Image Figure 23. Other Image Figure 24. Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Application (2021-2032) Figure 27. Global Monoclonal Antibody VEGF Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application (2021-2032) Figure 30. Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Monoclonal Antibody VEGF Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. North America Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 41. South America Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Monoclonal Antibody VEGF Inhibitors Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Monoclonal Antibody VEGF Inhibitors Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Bevacizumab
  • Brolucizumab
  • Faricimab
  • Ramucirumab
  • Ranibizumab
  • Other
Applications
  • Degenerative Eye Diseases
  • Cancer
  • Other
Companies covered
  • Amgen
  • Amneal Pharmaceuticals,
  • Celltrion Healthcare
  • Coherus BioSciences
  • Eli Lilly
  • Novartis
  • Pfizer
  • Roche
  • Boan Biotech
  • Jiangsu Hengrui Pharmaceuticals
  • Qilu Pharma
  • SinoCellTech
  • Innovent
  • Chia Tai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Monoclonal Antibody VEGF Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Monoclonal Antibody VEGF Inhibitors Market Dynamics
  1. 2.1 Monoclonal Antibody VEGF Inhibitors Industry Trends
  2. 2.2 Monoclonal Antibody VEGF Inhibitors Industry Drivers
  3. 2.3 Monoclonal Antibody VEGF Inhibitors Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody VEGF Inhibitors Industry Restraints
3 Monoclonal Antibody VEGF Inhibitors Market by Company
  1. 3.1 Global Monoclonal Antibody VEGF Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Monoclonal Antibody VEGF Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Monoclonal Antibody VEGF Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Monoclonal Antibody VEGF Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Monoclonal Antibody VEGF Inhibitors Company Product Type and Application
  8. 3.8 Global Monoclonal Antibody VEGF Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Monoclonal Antibody VEGF Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Monoclonal Antibody VEGF Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Monoclonal Antibody VEGF Inhibitors Market by Type
  1. 4.1 Monoclonal Antibody VEGF Inhibitors Type Introduction
  2. 4.1.1 Bevacizumab
  3. 4.1.2 Brolucizumab
  4. 4.1.3 Faricimab
  5. 4.1.4 Ramucirumab
  6. 4.1.5 Ranibizumab
  7. 4.1.6 Other
  8. 4.2 Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Type
  9. 4.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Type
  13. 4.3.1 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Type (2021-2032)
  15. 4.3.3 Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type (2021-2032)
5 Monoclonal Antibody VEGF Inhibitors Market by Application
  1. 5.1 Monoclonal Antibody VEGF Inhibitors Application Introduction
  2. 5.1.1 Degenerative Eye Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Application
  6. 5.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Monoclonal Antibody VEGF Inhibitors Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Application
  10. 5.3.1 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Application (2021-2032)
  12. 5.3.3 Global Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application (2021-2032)
6 Monoclonal Antibody VEGF Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Monoclonal Antibody VEGF Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Monoclonal Antibody VEGF Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Monoclonal Antibody VEGF Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Monoclonal Antibody VEGF Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Monoclonal Antibody VEGF Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Monoclonal Antibody VEGF Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Monoclonal Antibody VEGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Monoclonal Antibody VEGF Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Monoclonal Antibody VEGF Inhibitors Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Amneal Pharmaceuticals,
  8. 8.2.1 Amneal Pharmaceuticals, Company Information
  9. 8.2.2 Amneal Pharmaceuticals, Business Overview
  10. 8.2.3 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product Portfolio
  12. 8.2.5 Amneal Pharmaceuticals, Recent Developments
  13. 8.3 Celltrion Healthcare
  14. 8.3.1 Celltrion Healthcare Company Information
  15. 8.3.2 Celltrion Healthcare Business Overview
  16. 8.3.3 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product Portfolio
  18. 8.3.5 Celltrion Healthcare Recent Developments
  19. 8.4 Coherus BioSciences
  20. 8.4.1 Coherus BioSciences Company Information
  21. 8.4.2 Coherus BioSciences Business Overview
  22. 8.4.3 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product Portfolio
  24. 8.4.5 Coherus BioSciences Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Monoclonal Antibody VEGF Inhibitors Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Monoclonal Antibody VEGF Inhibitors Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Monoclonal Antibody VEGF Inhibitors Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Roche Monoclonal Antibody VEGF Inhibitors Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 Boan Biotech
  50. 8.9.1 Boan Biotech Company Information
  51. 8.9.2 Boan Biotech Business Overview
  52. 8.9.3 Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Boan Biotech Monoclonal Antibody VEGF Inhibitors Product Portfolio
  54. 8.9.5 Boan Biotech Recent Developments
  55. 8.10 Jiangsu Hengrui Pharmaceuticals
  56. 8.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
  57. 8.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  58. 8.10.3 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product Portfolio
  60. 8.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  61. 8.11 Qilu Pharma
  62. 8.11.1 Qilu Pharma Company Information
  63. 8.11.2 Qilu Pharma Business Overview
  64. 8.11.3 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product Portfolio
  66. 8.11.5 Qilu Pharma Recent Developments
  67. 8.12 SinoCellTech
  68. 8.12.1 SinoCellTech Company Information
  69. 8.12.2 SinoCellTech Business Overview
  70. 8.12.3 SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 SinoCellTech Monoclonal Antibody VEGF Inhibitors Product Portfolio
  72. 8.12.5 SinoCellTech Recent Developments
  73. 8.13 Innovent
  74. 8.13.1 Innovent Company Information
  75. 8.13.2 Innovent Business Overview
  76. 8.13.3 Innovent Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Innovent Monoclonal Antibody VEGF Inhibitors Product Portfolio
  78. 8.13.5 Innovent Recent Developments
  79. 8.14 Chia Tai Tianqing
  80. 8.14.1 Chia Tai Tianqing Company Information
  81. 8.14.2 Chia Tai Tianqing Business Overview
  82. 8.14.3 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product Portfolio
  84. 8.14.5 Chia Tai Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Monoclonal Antibody VEGF Inhibitors Value Chain Analysis
  2. 9.1.1 Monoclonal Antibody VEGF Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Monoclonal Antibody VEGF Inhibitors Sales Mode & Process
  6. 9.2 Monoclonal Antibody VEGF Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Monoclonal Antibody VEGF Inhibitors Distributors
  9. 9.2.3 Monoclonal Antibody VEGF Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst